Pfizer Inc. (PFE)

38.46
0.19 0.50
NYSE
Prev Close 38.27
Open 38.30
Day Low/High 38.16 / 38.62
52 Wk Low/High 27.88 / 40.97
Volume 14.08M
Exchange NYSE
Shares Outstanding 5554.83B
Market Cap 213.58B
P/E Ratio 13.73
Div & Yield N.A. (N.A)
Buy Stocks That Are Down, Not Up, Here

Buy Stocks That Are Down, Not Up, Here

Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

Best Tech Stocks to Buy -- No Matter What Apple Reports

Best Tech Stocks to Buy -- No Matter What Apple Reports

Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Jim Cramer: Sometimes You Just Have to Go Against the Grain

Jim Cramer: Sometimes You Just Have to Go Against the Grain

This market is all about being opportunistic.

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

For Pfizer, China is third largest market and a growing area of concern.

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

We believe the company has double-digit total return potential at its current price.

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer reorganization could pave way for the company to spin off businesses.

Jim Cramer Reacts to Pfizer's Reorganization

Jim Cramer Reacts to Pfizer's Reorganization

Pfizer announced plans Wednesday to reorganize into three units.

Pfizer Doesn't Look Fundamentally or Technically Strong

Pfizer Doesn't Look Fundamentally or Technically Strong

The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.

Jim Cramer: The Money Isn't Leaving the Casino

Jim Cramer: The Money Isn't Leaving the Casino

The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Here are the business stories you must know as U.S. stock futures fall sharply.

More From the Tweeter in Chief

Stocks are off of their day's highs, and Pfizer has pulled back on a Trump tweet: Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, w...

How to Play Pfizer's Fresh Upside Breakout

How to Play Pfizer's Fresh Upside Breakout

A bullish strategy for traders of PFE stock.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Is Goldman Sachs Going to Be the Next Allergan?

Is Goldman Sachs Going to Be the Next Allergan?

Don't count on it. The fundamentals paint two very different pictures, Cramer says.

Pfizer Rated 'New Overweight' at Cantor

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

Small-Cap Biotech and Tech Names Part of Our Latest 'Sweet 16' Stock Picks

Small-Cap Biotech and Tech Names Part of Our Latest 'Sweet 16' Stock Picks

Real Money stock picks from Tim Collins, Skip Raschke, Jim Collins and Bret Jensen.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Let's see what barriers may need to be passed before it heads its way higher.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

Intermediate Trade: Pfizer

Intermediate Trade: Pfizer

I prefer a bullishly biased vertical call spread.

Video: This Strategist Wants You to Take Advantage of the Recent Market Pullback

Video: This Strategist Wants You to Take Advantage of the Recent Market Pullback

It's time to start putting money to work in the stock market, thanks to this week's stock market pullback, especially if you have been sitting on the sidelines, according to one expert.

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

You might actually be grateful that stocks took one on the jaw on Monday.